Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Spiro Rombotis
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
cancer therapeutics
cell cycle biology |
| gptkbp:foundedYear |
1996
|
| gptkbp:founder |
gptkb:Sir_David_Lane
|
| gptkbp:headquartersLocation |
gptkb:Berkeley_Heights,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cyclacel Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
fadraciclib
sapacitabine |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:CYCC
|
| gptkbp:website |
https://www.cyclacel.com/
|
| gptkbp:bfsParent |
gptkb:CYC202
gptkb:Seliciclib |
| gptkbp:bfsLayer |
7
|